Mark Munch Sells 2,000 Shares of Bruker (NASDAQ:BRKR) Stock

Bruker Corporation (NASDAQ:BRKR) VP Mark Munch sold 2,000 shares of the stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $35.44, for a total transaction of $70,880.00. Following the completion of the transaction, the vice president owned 128,443 shares of the company’s stock, valued at $4,552,019.92. This represents a 1.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Mark Munch also recently made the following trade(s):

• On Thursday, January 15th, Mark Munch sold 2,000 shares of Bruker stock. The shares were sold at an average price of $49.20, for a total transaction of $98,400.00.
• On Monday, January 12th, Mark Munch sold 7,000 shares of Bruker stock. The stock was sold at an average price of $55.00, for a total transaction of $385,000.00.

Bruker Price Performance

Shares of NASDAQ:BRKR traded down $0.99 during trading on Monday, reaching $32.76. The company had a trading volume of 3,410,771 shares, compared to its average volume of 2,513,968. The firm’s fifty day moving average is $43.50 and its 200 day moving average is $41.11. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73. The firm has a market capitalization of $4.99 billion, a PE ratio of -218.40, a price-to-earnings-growth ratio of 2.02 and a beta of 1.19. Bruker Corporation has a twelve month low of $28.53 and a twelve month high of $56.22.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The company had revenue of $977.20 million for the quarter, compared to analyst estimates of $964.61 million. During the same quarter in the prior year, the business earned $0.76 EPS. Bruker’s revenue was down .2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities analysts forecast that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd will be given a dividend of $0.05 per share. The ex-dividend date is Monday, March 23rd. This represents a $0.20 annualized dividend and a dividend yield of 0.6%. Bruker’s dividend payout ratio (DPR) is -133.33%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BRKR. Orbis Allan Gray Ltd boosted its stake in Bruker by 5.4% in the 4th quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company’s stock worth $702,256,000 after purchasing an additional 761,258 shares during the period. State Street Corp boosted its position in Bruker by 2.5% during the fourth quarter. State Street Corp now owns 3,831,814 shares of the medical research company’s stock valued at $180,700,000 after purchasing an additional 91,706 shares during the last quarter. AQR Capital Management LLC lifted its stake in Bruker by 125.3% in the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after acquiring an additional 1,850,215 shares during the last quarter. Sculptor Capital LP lifted its position in shares of Bruker by 18.3% in the second quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock worth $126,682,000 after buying an additional 476,363 shares during the last quarter. Finally, Brown Advisory Inc. grew its holdings in Bruker by 13.9% during the second quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company’s stock valued at $113,142,000 after purchasing an additional 336,026 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Bank of America upped their price objective on Bruker from $43.00 to $60.00 and gave the company a “buy” rating in a report on Monday, December 15th. Barclays lowered their target price on Bruker from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, February 13th. JPMorgan Chase & Co. upped their price target on shares of Bruker from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, December 15th. TD Cowen reduced their price objective on shares of Bruker from $53.00 to $43.00 and set a “hold” rating for the company in a research report on Friday, February 13th. Finally, Citigroup lowered their price objective on shares of Bruker from $53.00 to $40.00 and set a “neutral” rating on the stock in a research note on Friday, February 13th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bruker presently has a consensus rating of “Hold” and a consensus price target of $50.38.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.